A new review by K. Mansukhbhai Shekhda et al. evaluates the effects of NET therapies, including somatostatin analogues, molecular targeted therapy, peptide receptor radionuclide therapy and chemotherapy, on reproductive and sexual function in patients with NETs. 🔗 doi.org/10.1530/ERC-25-0500

In a new review, Borbála Szabó, Attila Patocs & Henriett Butz examine DNA methylation–demethylation cycle in PitNETs, highlight challenges of detecting cytosine modifications & outline emerging evidence linking altered demethylation to tumour biology. 🔗 doi.org/10.1530/ERC-26-0030

A new mini review by Mia Zol‑Hanlon and Neil Q. McDonald explores progress in defining RET receptor architecture & discusses current models for how distinct assemblies of GFL–GFRα–RET receptor complexes activate intrinsic RET tyrosine kinase to relay signals. 🔗 doi.org/10.1530/ERC-25-0322

🎉 Congratulations to Associate Professor Matti Gild, winner of the Emerging Leader Best Paper Award 2025 for her outstanding contribution to the field with the paper: “Evaluating the prognostic potential of circulating cell‑free DNA in advanced thyroid cancer” 🔗 doi.org/10.1530/ERC-24-0227

Amongst the many cool things, we: - characterised SOX2+ expressing cells across PPGLs - identified expression signatures associated with metastatic potential - identified changes in expression between SOX2+ high versus SOX2+ low samples The paper is now out in @endocancer.bsky.social

I’m really glad to have been a part of this exciting project studying rare neuroendocrine tumours called phaeochromocytomas and paragangliomas. We performed 10x Genomics single-cell/nucleus RNA-seq on 7 PPGL patients, and integrated published data from another 12 patients. doi.org/10.1530/ERC-...

New research by Akitada Yogo et al. characterises microscopic small‑intestinal neuroendocrine tumorlets (SINTs) found in multifocal SI‑NETs, assessing their clinicopathological features and possible roles in multifocal tumorigenesis. 🔗 Read the research: doi.org/10.1530/ERC-25-0425

The WorldMEN 2025 Special Collection is inviting complementary papers from researchers who weren't able to attend the event but whose work meaningfully contributes to understanding the unmet needs in multiple endocrine neoplasia syndromes. Learn more: erc.bioscientifica.com/page/WorldMEN-2025

A new review by Virginia Corbett, Garima Gupta, and Aman Chauhan synthesises recent clinical trials, cohort studies, and expert consensus to clarify the role of peptide receptor radionuclide therapy in neuroendocrine tumours management. Read the review #OpenAccess: doi.org/10.1530/ERC-...

Pituitary neuroendocrine tumours (PitNETs) in elderly people (≥65 years) is increasing as life expectancy rises. A new review examines the biology & clinical features of PitNETs in elderly people to support further research in this patient population. 🔗 doi.org/10.1530/ERC-25-0535

New research by Nilakshi Kulathunga et al. investigates whether the avian chorioallantoic membrane can support engraftment of tumour fragments from well‑differentiated NETs. 🔗Read the research #OpenAccess: doi.org/10.1530/ERC-25-0377

Giant cell tumours rarely occur in the skull. A new review summarises current understanding about these cases, reporting 79 sphenoid GCTs & adding 2 new cases. This article forms part of our Emerging Leader Collection, featuring rising researcher Fanny Chasseloup 👏 🔗 doi.org/10.1530/ERC-24-0289

A new study by Qianjin Guo et al. leveraged human SDHB-deficient UOK269 RCC cells (SDHB-KO) and isogenic SDHB-reconstituted control cells (SDHB-WT) to identify intrinsic susceptibilities of SDHB-deficient cancers that could be therapeutically leveraged. Read the article: doi.org/10.1530/ERC-25-0397

Alisson Clemenceau et al. synthesises over 3 decades of human observational studies, using systematic review & meta‑analyses to examine how PTHrP relates to prognostic tumour characteristics & patient outcomes in women with breast cancer. Read the full study #OpenAccess: doi.org/10.1530/ERC-25-0324

🆕 NANETS Guidelines for the diagnosis and management of stage I–III rectal neuroendocrine tumors 🔗 doi.org/10.1530/ERC-25-0303

Can GLP-1 receptor agonists, used to treat diabetes and obesity, play a role in #ProstateCancer? A new study from University of Illinois Chicago researchers, published in @endocancer.bsky.social#ProstateCancer explores the link. Read more: https://bit.ly/4kRIonU

What is the clinical relevancy of germline & somatic SDHA pathogenic/likely pathogenic (P/LP) variants in cancer patients? A recent comprehensive analysis by Henriett Butz et al. investigates prevalence & clinical relevance of germline & somatic SDHA P/LP variants. doi.org/10.1530/ERC-25-0281

Jonathan R Strosberg et al. publish a subgroup analysis of the phase 3 CABINET trial, evaluating outcomes in patients with well-differentiated grade 3 neuroendocrine tumours (G3 NETs; Ki-67 > 20%). Read the article: doi.org/10.1530/ERC-25-0415

Call for Papers: The Biology of Aging and Endocrine‑Related Cancers This collection aims to improve understanding of how aging biology influences endocrine‑related cancer risk, treatment responses, and patient outcomes. For more info visit: erc.bioscientifica.com/page/Biology-of-Aging

How does ageing shape adrenal tumours? A new mini-review by Abel Decmann et al. summarises how age‑related changes in the adrenal cortex and medulla, from structural remodelling to shifts in immune & cellular balance, may influence tumorigenesis. Read the article: doi.org/10.1530/ERC-25-0150

Marking 30 years, the RET@Thirty Special Collection features an exclusive editorial with Professor Sir Bruce Ponder & brings together mini-reviews addressing the multifaceted aspects of RET & its impact on clinical practice. Explore the collection: erc.bioscientifica.com/page/RET@Thirty

Could AIP loss-of-function contribute to neuroendocrine neoplasms (NENs) beyond pituitary tumours? Blanca R Carranza-Zavala et al. investigated the prevalence and in‑vitro effects of germline AIP variants in Mexican patients with NENs. 🔓 Full research #OpenAccess: doi.org/10.1530/ERC-25-0095

A new study by Marijn L van den Berg et al. analyses long‑term calcitonin trends in 52 MEN2A patients after total thyroidectomy, revealing distinct postoperative patterns that could inform more personalised surveillance. 🔓 Read the full article: doi.org/10.1530/ERC-25-0366

🌟 We take pride in our annual Emerging Leaders Special Collection, celebrating the knowledge & talent of exceptional early‑career scientists shaping the future of the field. Explore the researchers and articles featured in our 2025 collection: erc.bioscientifica.com/page/emerging-leaders-2025

🚀 The new year marks an exciting transition for Endocrine-Related Cancer as Prof. Karel Pacak begins his term as Editor-in-Chief! In a new editorial, Prof. Pacak outlines 5 principles that will guide the journal as a platform for collaboration, inspiration & progress: doi.org/10.1530/ERC-25-0497

A new review by Hans V. Westerhoff explores how complexity, plasticity and circular causality make intracellular networks resemble trained neural networks. Comparing disease challenges with those in evolution or development may reveal 'learned' cellular responses. 🔗 doi.org/10.1530/ERC-25-0183

We are delighted to welcome Professor Ilan Shimon, MD, as a new Associate Editor for Endocrine‑Related Cancer. A leading clinical academic endocrinologist and former ENEA President, he brings extensive expertise in pituitary tumour research. 🔗 erc.bioscientifica.com

📊 Real-world survival outcomes in neuroendocrine neoplasms (NENs) A retrospective study by Marta Laganà et al. analysed 239 patients with NENs (2010–2023), reporting overall survival (OS), progression-free survival (PFS), and key predictors. Read the article: doi.org/10.1530/ERC-25-0243

New research by Soumen Bera et al. supports a model where GLP1R agonism blocks oncogenic pathways and growth of prostate cancer cells, pointing to potential therapeutic applications of semaglutide in advanced prostate cancer. 👉 Read the article: doi.org/10.1530/ERC-25-0185

⭐ Which articles are shaping the conversation in endocrine oncology? Our incoming Editor‑in‑Chief, Professor Karel Pacak, has curated his first Editors’ Choice Collection. 📚 Explore the collection: erc.bioscientifica.com/page/edchoice/editors-choice

A new narrative review by Michaela Kuhlen, Marina Kunstreich and Antje Redlich explores how paediatric and adult DTC differ across biology, presentation, treatment strategies and guidelines, highlighting the need for harmonised, age‑specific approaches. doi.org/10.1530/ERC-25-0191

Spotlighting our latest completed collections & our open collections for submissions. ✅ 𝗖𝗼𝗺𝗽𝗹𝗲𝘁𝗲𝗱 𝗖𝗼𝗹𝗹𝗲𝗰𝘁𝗶𝗼𝗻𝘀: 🔎 𝙍𝙀𝙏@𝙏𝙝𝙞𝙧𝙩𝙮 - bit.ly/4p9qspY 🔬 𝙏𝙝𝙚 𝙒𝙖𝙧𝙗𝙪𝙧𝙜 𝙀𝙛𝙛𝙚𝙘𝙩 - bit.ly/4rb6eOs 💡 𝗢𝗽𝗲𝗻 𝗳𝗼𝗿 𝗦𝘂𝗯𝗺𝗶𝘀𝘀𝗶𝗼𝗻𝘀: 🌱 𝙃𝙚𝙧𝙞𝙩𝙖𝙗𝙡𝙚 𝙀𝙣𝙙𝙤𝙘𝙧𝙞𝙣𝙚 𝘾𝙖𝙣𝙘𝙚𝙧𝙨 - bit.ly/43A22O7 🧠 𝙋𝙞𝙩𝙪𝙞𝙩𝙖𝙧𝙮 𝙏𝙪𝙢𝙤𝙪𝙧𝙨 - bit.ly/4p9qTk6

Please join us in welcoming Dr. Crona to the Endocrine-Related Cancer community. Dr. Crona is Associate Professor at Uppsala University, Sweden, and a clinical oncologist with a special interest in endocrine neoplasia.🚀

🏆 As we approach the end of 2025, we’re launching the Endocrine-Related Cancer Best Paper Award - celebrating the most outstanding articles published in 2025. Papers will be selected by our editorial leadership, with 1st place awarded £1000 💜 Stay tuned, selection will take place in 2026!

Today, we stand with the global community in recognising everyone affected by neuroendocrine cancer. At Endocrine-Related Cancer, we remain committed to publishing high-quality research that advances understanding of NETs to optimise patient care. 🔗 lnkd.in/eBY6uA_r #WorldNeuroendocrineCancerDay

We’re excited to announce a new Special Collection featuring the most significant clinical & scientific presentations from the 7th International Symposium on Pheochromocytoma. 🔗 For more info: lnkd.in/d3gyVVbg Collection Editors: Prof. Isabelle Bourdeau, Prof. Karel Pacak & Prof. André Lacroix

🎉 Excited to share our new publication! Targeted inhibition of netrin–DCC axis with NP137 reverses netrin-driven survival in vitro & reduces high-grade pancreatic NEN progression in vivo. Potential therapeutic strategy for aggressive PNENs? bit.ly/435pKBx @endocancer.bsky.social

Lenvatinib is preferred over sorafenib as first-line therapy for RR‑DTC due to superior PFS. Vincenzo Marotta et al. compared both MKIs in a real‑world, treatment‑naïve cohort: lenvatinib showed higher activity, but no OS benefit. Subscribers can read the article: doi.org/10.1530/ERC-24-0215

🧬 Results from clinical trial NCT03969121: Neoadjuvant Hormonal Therapy Plus Palbociclib in Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer. Now available in Endocrine-Related Cancer #OpenAccess: doi.org/10.1530/ERC-24-0353

Early-Career Editor Opening! A great opportunity for early-career researchers to build editorial experience, gain mentorship & shape research. To apply, send your CV and cover letter to [email protected] by 7 Nov 2025. Questions? Reach out to [email protected]

New research by Di Sun et al. investigates the long-term efficacy of anlotinib in patients with progressive RAIR-DTC and explores the predictive potential of PET/CT parameters. 🔗 Subscribers of Endocrine-Related Cancer can read the full article: doi.org/10.1530/ERC-25-0027

New retrospective cohort study by Branislav Klimacek et al. explores the non-operative management of initially asymptomatic patients diagnosed with small intestine neuroendocrine tumors, raising questions about current guidelines. Read the full study here #OpenAccess: doi.org/10.1530/ERC-25-0205

Be part of the global #neuroendocrinecancer research conversation in Boston, November 17-19. The NETRF (@netrf.org) Annual Research Symposium brings together expert researchers to share leading-edge science and learn from each other. Register now: bit.ly/4nQ9goU #NETresearch #cancerresearch

Neoadjuvant Palbociclib Plus Endocrine Therapy Does Not Improve PEPI Scores in Resectable HR+ Breast Cancer #BreastCancer #BCSM @endocancer.bsky.social www.onclive.com/view/neoadju...

Explore the latest in #pheochromocytoma & #paraganglioma research with Endocrine-Related Cancer’s (@endocancer.bsky.social) special collection, featuring recent advances in genetics, metabolomics, nuclear medicine & more. Explore the collection: erc.bioscientifica.com/page/PPGL

🔬 Discovery of a novel sodium iodide symporter regulatory pathway in breast cancer cells. Vikki L Poole et al. opens new therapeutic avenues in #BreastCancer by mapping sodium iodide symporter regulation & pinpointing targets to boost radioiodide avidity. Read #OpenAccess: doi.org/10.1530/ERC-...

New research by Exequiel Gonzalo Alonso et al. uncovers a protumor role for HO-1 in thyroid cancer by enhancing proliferation, migration & cell cycle progression. 🔎 🎯Could HO-1 be a therapeutic target? Subscribers can read the research: doi.org/10.1530/ERC-25-0177 #ThyroidCancer #CancerResearch

🧠Contribute to Endocrine-Related Cancer's new Special Collection on pituitary tumours! We welcome basic, translational & clinical studies that advance understanding & showcase innovations in the field. 📩Submit your proposal to: [email protected] 🌐More info: bit.ly/4mUXslc

🎯Targeting RET in medullary thyroid cancer has played a key role in therapeutic strategies in the past decade. A new review by Kate Newbold and Leslie Cheng explores targeted and selective RET therapies, and highlights the challenge of resistance. 🔗 doi.org/10.1530/ERC-24-0291

🌱Endocrine-Related Cancer is officially on LinkedIn! Follow our new profile to stay up to date with the latest articles, special collections and updates from the journal. 🌐 linkedin.com/company/endocrine-related-cancer/ #MedSky #CancerResearch #EndocrineOncology #HormoneCancers